17 results on '"Anthony R Fooks"'
Search Results
2. New human rabies vaccines in the pipeline
- Author
-
Hildegund C.J. Ertl, Anthony R. Fooks, and Ashley C. Banyard
- Subjects
Rabies ,030231 tropical medicine ,Drug Evaluation, Preclinical ,Disease ,medicine.disease_cause ,Multiple dosing ,Article ,Rabies immune globulin (RIG) ,03 medical and health sciences ,0302 clinical medicine ,Drug Development ,Correlates of protection ,Drug Discovery ,Medicine ,Humans ,030212 general & internal medicine ,Clinical Trials as Topic ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Post-exposure prophylaxis (PEP) ,Rabies virus ,Public Health, Environmental and Occupational Health ,Human rabies vaccines ,medicine.disease ,Virology ,Vaccination ,Infectious Diseases ,Death toll ,Rabies Vaccines ,Molecular Medicine ,Pre-Exposure Prophylaxis ,Rabies control ,business ,Post-Exposure Prophylaxis ,Pre-exposure prophylaxis (or PrEP) - Abstract
Rabies remains endemic in more than 150 countries. In 99% of human cases, rabies virus is transmitted by dogs. The disease, which is nearly always fatal, is preventable by vaccines given either before and/or after exposure to a rabid animal. Numerous factors including the high cost of vaccines, the relative complexity of post-exposure vaccination protocols requiring multiple doses of vaccine, which in cases of severe exposure have to be combined with a rabies immune globulin, lack of access to health care, and insufficient surveillance contribute to the estimated 59,000 human deaths caused by rabies each year. New, less expensive and more immunogenic rabies vaccines are needed together with improved surveillance and dog rabies control to reduce the death toll of human rabies. Here, we discuss new rabies vaccines that are in clinical and pre-clinical testing and evaluate their potential to replace current vaccines.
- Published
- 2019
3. Mannitol treatment is not effective in therapy of rabies virus infection in mice
- Author
-
Václav Hönig, Penelope Koraka, Jiri Salat, Albert D. M. E. Osterhaus, Daniel Ruzek, Lucie Dufkova, Noël Tordo, Dirk Jochmans, Byron E. E. Martina, Karen L. Mansfield, Jana Širmarová, Martin Palus, Anthony R. Fooks, Johan Neyts, and Virology
- Subjects
Central Nervous System ,0301 basic medicine ,Rabies ,medicine.medical_treatment ,Intraperitoneal injection ,Pharmacology ,Antibodies, Viral ,medicine.disease_cause ,Blood–brain barrier ,Virus ,Mice ,03 medical and health sciences ,Immune system ,Animals ,Medicine ,Mannitol ,Antigens, Viral ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Rabies virus ,Public Health, Environmental and Occupational Health ,medicine.disease ,Mice, Inbred C57BL ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,Blood-Brain Barrier ,Molecular Medicine ,Female ,Viral disease ,business ,medicine.drug - Abstract
Rabies is a deadly viral disease with an extremely high fatality rate in humans. Previously, it was suggested that an enhancement of the blood-brain barrier (BBB) permeability, which allows immune cells and/or antibodies to enter the central nervous system (CNS) tissue, is critical to clear the infection. In this study, we utilised mannitol to increase BBB permeability in mice infected with highly pathogenic silver-haired bat rabies virus (SHBRV). We found that intraperitoneal injection of mannitol causes a slight, transient increase of BBB permeability in the treated mice. SHBRV-infected mice were treated with intraperitoneally administered mannitol daily from day 3 or day 4 post-infection, but no effect of this treatment on the time of disease onset, clinical signs or survival was observed. This data indicates that the increase of BBB permeability by mannitol is not efficient in promoting CNS virus clearance in SHBRV-infected mice.
- Published
- 2019
4. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans
- Author
-
Kevin E. Brown, Lorraine M. McElhinney, Trudy Goddard, Anthony R. Fooks, Hooman Goharriz, Karen L. Mansfield, and Nick Andrews
- Subjects
Adult ,Male ,Time Factors ,Endemic Diseases ,Injections, Intradermal ,Rabies ,030231 tropical medicine ,Immunization, Secondary ,Antibodies, Viral ,Cohort Studies ,03 medical and health sciences ,Pre-exposure prophylaxis ,Sex Factors ,0302 clinical medicine ,Immunity ,Humans ,Medicine ,030212 general & internal medicine ,Vaccine Potency ,Immunization Schedule ,Travel ,Booster (rocketry) ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,medicine.disease ,Antibodies, Neutralizing ,Vaccination ,Titer ,Infectious Diseases ,Rabies Vaccines ,Immunology ,Cohort ,biology.protein ,Molecular Medicine ,Female ,Pre-Exposure Prophylaxis ,Antibody ,business - Abstract
Despite the availability of safe and effective human vaccines, rabies remains a global threat, with an estimated 60,000 human deaths annually attributed to rabies. Pre-exposure prophylaxis against rabies infection is recommended for travelers to countries where rabies is endemic, and also for those with a higher risk of exposure. In this study, the rabies-specific neutralising antibody responses in a cohort of rabies-vaccinated recipients over a period of twenty years have been assessed. In particular, the antibody response to primary vaccinations and boosters, and the waning of antibody post primary vaccination and post booster were investigated. The significance of gender, age at vaccination, vaccine manufacturer and vaccination intervals were also evaluated. These data confirm that rabies vaccination can elicit a neutralising antibody response that can remain at detectable levels for a number of years, without additional booster vaccinations. The antibody response following both primary vaccination and booster was significantly influenced by the gender of the subject (p=0.002 and 0.03 respectively), with supportive data that suggests an effect by the make of vaccine administered following primary vaccination, with significantly higher VNA titres observed for one vaccine manufactured prior to 2006 (p
- Published
- 2016
5. Preface
- Author
-
Linda H.L. Lua and Anthony R. Fooks
- Subjects
Vaccines ,Infectious Diseases ,General Veterinary ,General Immunology and Microbiology ,Biosurveillance ,Communicable Disease Control ,Public Health, Environmental and Occupational Health ,Molecular Medicine ,Animals ,Humans ,Biological Warfare Agents ,Bioterrorism - Published
- 2017
6. Feasibility and efficacy of oral rabies vaccine SAG2 in endangered Ethiopian wolves
- Author
-
Ashley C. Banyard, Alo Hussein, Jorgelina Marino, Claudio Sillero-Zubiri, Chris H. Gordon, Eric Bedin, Fekede Regassa, and Anthony R. Fooks
- Subjects
0301 basic medicine ,Veterinary medicine ,Rabies ,030231 tropical medicine ,Population ,Endangered species ,Wildlife ,Administration, Oral ,Animals, Wild ,03 medical and health sciences ,0302 clinical medicine ,Rabies vaccine ,parasitic diseases ,medicine ,Animals ,education ,education.field_of_study ,Wolves ,General Veterinary ,General Immunology and Microbiology ,biology ,Endangered Species ,Vaccination ,Public Health, Environmental and Occupational Health ,Outbreak ,biology.organism_classification ,medicine.disease ,030104 developmental biology ,Infectious Diseases ,Canis ,Rabies Vaccines ,Molecular Medicine ,Ethiopia ,medicine.drug - Abstract
Diseases are a major cause of population declines in endangered populations of several canid species. Parenteral vaccination efforts to protect Ethiopian wolves (Canis simensis) from rabies have targeted the domestic dog reservoir, or the wolves themselves in response to confirmed outbreaks. Oral vaccination offers a more cost-efficient, safe and proactive approach to protect Ethiopian wolves and other threatened canids from rabies. Field trials of the oral vaccine Rabigen® SAG2Dog were undertaken in the Bale Mountains of southeastern Ethiopia. Four different bait types and three delivery methods were tested in twelve Ethiopian wolf packs, and the oral vaccine (using the preferred bait) was trialled in three packs. Vaccine uptake and immunization rates were measured through direct observations and in live-trapped animals through the assessment of biomarker levels and serological status. Commercial baits were never taken by wolves; goat meat baits had the highest uptake, compared to rodent and intestine baits. Targeted delivery from horseback and nocturnal delivery within a pack's territory performed favourably compared to random bait distribution. Bait uptake by non-target species was lowest during the nocturnal blind distribution. Of 21 wolves trapped after vaccination, 14 were positive for the biomarker iophenoxic acid (i.e. ingested the bait and most likely pierced the sachet with the vaccine). Of these, 86% (n=12/14) had levels considered sufficient to provide protective immunity to wildlife (⩾0.20IU/ml), and 50% (n=7/14) demonstrated antibody titres above the universally recognised threshold (⩾0.5IU/ml) -the baseline average was 0.09IU/ml (n=12 wolves). All but one of the wolves vaccinated in 2014 were alive 14months later. Our trials confirm the potential for SAG2, delivered in a goat meat bait, to effectively protect Ethiopian wolves against rabies, supporting the initiative for a more efficient and proactive approach to manage and eventually eliminate rabies in Ethiopian wolf populations.
- Published
- 2016
7. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa
- Author
-
Tiziana Lembo, Trudy Goddard, Daniel L. Horton, Anthony R. Fooks, Robin A. Weiss, Louis Hendrik Nel, Suzanne McNabb, Sarah Cleaveland, and Edward Wright
- Subjects
Male ,Antibodies, Viral ,medicine.disease_cause ,Tanzania ,Pseudotype ,Blood serum ,Viral Envelope Proteins ,Seroepidemiologic Studies ,Dog Diseases ,Mononegavirales ,0303 health sciences ,biology ,3. Good health ,Infectious Diseases ,Duvenhage virus ,Molecular Medicine ,Female ,Lagos bat virus ,Rabies ,Mokola virus ,Sensitivity and Specificity ,Article ,03 medical and health sciences ,Dogs ,Neutralization Tests ,Immunology and Microbiology(all) ,medicine ,Animals ,Lyssavirus ,030304 developmental biology ,General Veterinary ,General Immunology and Microbiology ,030306 microbiology ,Lentivirus ,Rabies virus ,Public Health, Environmental and Occupational Health ,biology.organism_classification ,medicine.disease ,Virology ,veterinary(all) ,Rabies Vaccines ,Africa - Abstract
The inflexibility of existing serological techniques for detection of rabies in surveillance constrains the benefit to be gained from many current control strategies. We analysed 304 serum samples from Tanzanian dogs for the detection of rabies antibodies in a pseudotype assay using lentiviral vectors bearing the CVS-11 envelope glycoprotein. Compared with the widely used gold standard fluorescent antibody virus neutralisation assay, a specificity of 100% and sensitivity of 94.4% with a strong correlation of antibody titres (r = 0.915) were observed with the pseudotype assay. To increase the assay's surveillance specificity in Africa we incorporated the envelope glycoprotein of local viruses, Lagos bat virus, Duvenhage virus or Mokola virus and also cloned the lacZ gene to provide a reporter element. Neutralisation assays using pseudotypes bearing these glycoproteins reveal that they provide a greater sensitivity compared to similar live virus assays and will therefore allow a more accurate determination of the distribution of these highly pathogenic infections and the threat they pose to human health. Importantly, the CVS-11 pseudotypes were highly stable during freeze-thaw cycles and Storage at room temperature. These results suggest the proposed pseudotype assay is a suitable option for undertaking lyssavirus serosurveillance in areas most affected by these infections. (C) 2009 Elsevier Ltd. All rights reserved.
- Published
- 2009
- Full Text
- View/download PDF
8. Intradermal pre-exposure rabies vaccine elicits long lasting immunity
- Author
-
Elizabeth Lloyd, John J. Featherstone, David R. Brown, Anthony R. Fooks, Sharmeen Gettner, and Martin Schweiger
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Injections, Intradermal ,Rabies ,Immunization, Secondary ,Antibodies, Viral ,medicine.disease_cause ,Cohort Studies ,Rabies vaccine ,Immunity ,medicine ,Humans ,Dosing ,Lyssavirus ,Aged ,Retrospective Studies ,Aged, 80 and over ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Rabies virus ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Middle Aged ,medicine.disease ,biology.organism_classification ,Infectious Diseases ,Rabies Vaccines ,Immunization ,Immunology ,Molecular Medicine ,Female ,business ,medicine.drug - Abstract
A retrospective cohort study of current rabies antibody titres from adults who received pre-exposure immunisation administered intradermally between 1994 and 2005, examining the decay in titre over time relative to the interval since last dose, and the total dose received. Participants receiving at least 0.6 ml total dose intradermally of vaccine over at least two clinic visits and all with three clinic visits, were shown to have an adequate titre with measurable levels of antibody indicating sero-conversion above 0.5 IU/ml, irrespective of the time interval since the last dose. No clear relationship was found between time interval since immunisation and the level of antibody. Using a schedule that administers 0.6 ml of rabies vaccine over three clinic visits the boosting interval could be extended towards ten years; substantially cheaper than the standard licensed intramuscular dosing schedule.
- Published
- 2008
9. A recombinant pseudorabies virus expressing rabies virus glycoprotein: Safety and immunogenicity in dogs
- Author
-
Qianxue Li, Shoufeng Zhang, Fei Zhang, Zi-Guo Yuan, Anthony R. Fooks, Rongliang Hu, and Ye Liu
- Subjects
viruses ,Blotting, Western ,Pseudorabies ,Antibodies, Viral ,Recombinant virus ,medicine.disease_cause ,Cell Line ,Dogs ,Neutralization Tests ,Chlorocebus aethiops ,Pseudorabies Vaccines ,medicine ,Animals ,Dog Diseases ,Mononegavirales ,Vero Cells ,Lyssavirus ,Glycoproteins ,Duck embryo vaccine ,Vaccines, Synthetic ,General Veterinary ,General Immunology and Microbiology ,biology ,Vaccination ,Rabies virus ,Public Health, Environmental and Occupational Health ,Rhabdoviridae ,Flow Cytometry ,biology.organism_classification ,medicine.disease ,Herpesvirus 1, Suid ,Virology ,Blotting, Southern ,Infectious Diseases ,DNA, Viral ,Molecular Medicine ,Rabies - Abstract
Summary Several recombinant vaccines expressing the rabies virus glycoprotein have been developed, particularly for the oral vaccination of wildlife. While these vaccines induce protective immunity in some animal species such as foxes, they are less effective in others. Pseudorabies virus (PRV) has been licensed for use as a live vaccine in pigs and possesses an excellent safety and efficacy record. We have used it to construct a recombinant virus, rPRV/eGFP/rgp, expressing the rabies virus glycoprotein. This recombinant virus has been shown to be safe for dogs by oral and intramuscular routes of inoculation and was demonstrated to induce immune responses against both pseudorabies and rabies in dogs after a single oral dose of 2 × 10 7.0 plaque forming units (PFU). Neutralizing antibody titers against rabies reached >0.5 IU/ml and 1:64–1:128 against pseudorabies by 5 weeks post-vaccination in all dogs, indicating that the pseudorabies virus vector infected dogs and replicated in vivo , and that the rabies virus glycoprotein had been expressed and an effective immune response elicited. Antibody titers were maintained for over 6 months. This suggests that pseudorabies virus could be an effective live vector for recombinant rabies oral vaccination.
- Published
- 2008
10. Book review
- Author
-
Anthony R. Fooks
- Subjects
0301 basic medicine ,03 medical and health sciences ,Infectious Diseases ,General Veterinary ,General Immunology and Microbiology ,Evolutionary biology ,030106 microbiology ,Public Health, Environmental and Occupational Health ,Molecular Medicine ,Zoology ,Biology - Published
- 2016
11. Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?
- Author
-
Andrew J. Easton, Ashley C. Banyard, Anthony R. Fooks, Jennifer S. Evans, and Daniel L. Horton
- Subjects
General Veterinary ,General Immunology and Microbiology ,Animal health ,Occupational risk ,Rabies ,Rabies virus ,Public Health, Environmental and Occupational Health ,Genetic Variation ,Disease ,Biology ,biology.organism_classification ,medicine.disease ,medicine.disease_cause ,Virology ,Infectious Diseases ,Rabies Vaccines ,Genetic variation ,Antigenic variation ,medicine ,Molecular Medicine ,Animals ,Humans ,Lyssavirus - Abstract
All members of the lyssavirus genus are capable of causing disease that invariably results in death following the development of clinical symptoms. The recent detection of several novel lyssavirus species across the globe, in different animal species, has demonstrated that the lyssavirus genus contains a greater degree of genetic and antigenic variation than previously suspected. The divergence of species within the genus has led to a differentiation of lyssavirus isolates based on both antigenic and genetic data into two, and potentially a third phylogroup. Critically, from both a human and animal health perspective, current rabies vaccines appear able to protect against lyssaviruses classified within phylogroup I. However no protection is afforded against phylogroup II viruses or other more divergent viruses. Here we review current knowledge regarding the diversity and antigenicity of the lyssavirus glycoprotein. We review the degree of cross protection afforded by rabies vaccines, the genetic and antigenic divergence of the lyssaviruses and potential mechanisms for the development of novel lyssavirus vaccines for use in areas where divergent lyssaviruses are known to circulate, as well as for use by those at occupational risk from these pathogens.
- Published
- 2012
12. The immune response to rabies virus infection and vaccination
- Author
-
Adam F. Cunningham, Nicholas Johnson, and Anthony R. Fooks
- Subjects
Rabies ,medicine.disease_cause ,Antibodies, Viral ,Immune system ,Antigen ,medicine ,Humans ,Mononegavirales ,Neutralizing antibody ,Lyssavirus ,Antigens, Viral ,Antigen Presentation ,General Veterinary ,General Immunology and Microbiology ,biology ,Rabies virus ,Public Health, Environmental and Occupational Health ,medicine.disease ,biology.organism_classification ,Virology ,Antibodies, Neutralizing ,Vaccination ,Infectious Diseases ,Rabies Vaccines ,Immunology ,Antibody Formation ,biology.protein ,Molecular Medicine - Abstract
Infection with rabies virus causes encephalitis in humans that has a case fatality rate of almost 100%. This inability to resolve infection is surprising since both pre-exposure vaccination and, if given promptly, post-exposure vaccination is highly effective at preventing encephalitic disease. The principal immunological correlate of protection produced by vaccination is neutralizing antibody. T-helper cells contribute to the development of immunity whereas cytotoxic T cells do not appear to play a role in protection and may actually be detrimental to the host. One reason for a failure to protect in humans may be the poor immunological response the virus provokes, despite the period between exposure to virus and the development of disease being measured in months. Few individuals have measurable neutralizing antibody on presentation with disease, although in many cases this develops as symptoms become more severe. Furthermore, when antibody is detected in serum it rarely appears in cerebrospinal fluid suggesting limited penetration into the CNS, the site where it is most needed. The role of the modest mononuclear cell infiltrate into the brain parenchyma is unclear. Some studies suggest the virus can suppress cell-mediated immunity early during the infection although there is little mechanistic evidence to support this beyond suppression of intracellular interferon production by the viral phosphoprotein. In contrast, levels of antibody in the CNS correlate to the peak virus production within the CNS. Here we review the current understanding of immune responses to rabies infection and vaccination against this disease. This article identifies a need to understand how rabies antigens are initially presented and how this can influence the subsequent development of antibody responses. This could help identify ways in which the response to prophylactic vaccination can be enhanced and how the natural immune response to infection can be boosted to combat neuroinvasion.
- Published
- 2009
13. Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife
- Author
-
Noël Tordo, Nicholas Johnson, Aline Beckert, Franz Josef Conraths, Reto Zanoni, Anthony R. Fooks, Denise A. Marston, Susann Schares, Thomas Müller, Lorraine M. McElhinney, Bernd Hoffmann, Jeannette Kliemt, Lutz Geue, Christina Schnick, Conrad M. Freuling, Institute of Epidemiology (IfE), Friedrich-Loeffler-Institut (FLI), Institute of Diagnostic Virology (IVD), Vetsuisse Faculty, University of Bern, Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency, Stratégies Antivirales, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
MESH: Sequence Analysis, DNA ,Foxes ,Sequence Homology ,MESH: Base Sequence ,medicine.disease_cause ,MESH: INDEL Mutation ,chemistry.chemical_compound ,INDEL Mutation ,MESH: Animals ,MESH: Sequence Homology ,Mononegavirales ,MESH: Phylogeny ,Phylogeny ,Recombination, Genetic ,0303 health sciences ,biology ,MESH: Rabies Vaccines ,3. Good health ,MESH: Rabies virus ,Vaccination ,Europe ,Infectious Diseases ,MESH: RNA, Viral ,behavior and behavior mechanisms ,Molecular Medicine ,RNA, Viral ,MESH: Recombination, Genetic ,MESH: Genome, Viral ,psychological phenomena and processes ,Rabies ,Molecular Sequence Data ,MESH: Sequence Alignment ,Genome, Viral ,Vaccines, Attenuated ,behavioral disciplines and activities ,Virus ,03 medical and health sciences ,MESH: Rabies ,mental disorders ,MESH: Vaccines, Attenuated ,medicine ,Animals ,Lyssavirus ,030304 developmental biology ,MESH: Foxes ,MESH: Molecular Sequence Data ,General Veterinary ,General Immunology and Microbiology ,Base Sequence ,030306 microbiology ,Rabies virus ,Public Health, Environmental and Occupational Health ,Sequence Analysis, DNA ,Rhabdoviridae ,biology.organism_classification ,medicine.disease ,Virology ,chemistry ,Rabies Vaccines ,MESH: Europe ,Vaccinia ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,Sequence Alignment - Abstract
International audience; The elimination of rabies from the red fox (Vulpes vulpes) in Western Europe has been achieved by the oral rabies vaccination (ORV) of wildlife with a range of attenuated rabies virus strains. With the exception of the vaccinia rabies glycoprotein recombinant vaccine (VRG), all strains were originally derived from a common ancestor; the Street Alabama Dufferin (SAD) field strain. However, after more than 30 years of ORV it is still not possible to distinguish these vaccine strains and there is little information on the genetic basis for their attenuation. We therefore sequenced and compared the full-length genome of five commercially available SAD vaccine viruses (SAD B19, SAD P5/88, SAG2, SAD VA1 and SAD Bern) and four other SAD strains (the original SAD Bern, SAD VA1, ERA and SAD 1-3670 Wistar). Nucleotide sequencing allowed identifying each vaccine strain unambiguously. Phylogenetic analysis revealed that the majority of the currently used commercial attenuated rabies virus vaccines appear to be derived from SAD B19 rather than from SAD Bern. One commercially available vaccine virus did not contain the SAD strain mentioned in the product information of the producer. Two SAD vaccine strains appeared to consist of mixed genomic sequences. Furthermore, in-del events targeting A-rich sequences (in positive strand) within the 3' non-coding regions of M and G genes were observed in SAD-derivates developed in Europe. Our data also supports the idea of a possible recombination that had occurred during the derivation of the European branch of SAD viruses. If confirmed, this recombination event would be the first one reported among RABV vaccine strains.
- Published
- 2007
14. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies
- Author
-
Anthony R. Fooks, Ye Liu, Rongliang Hu, Shoufeng Zhang, and Fei Zhang
- Subjects
Rabies ,Administration, Oral ,Adenoviruses, Canine ,medicine.disease_cause ,Antibodies, Viral ,Rabies vaccine ,Dogs ,Neutralization Tests ,Vaccination of dogs ,Medicine ,Animals ,Dog Diseases ,Rabies transmission ,Lyssavirus ,Administration, Intranasal ,Duck embryo vaccine ,Vaccines, Synthetic ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Rabies virus ,Vaccination ,Public Health, Environmental and Occupational Health ,medicine.disease ,biology.organism_classification ,Virology ,Infectious Diseases ,Rabies Vaccines ,Immunology ,Molecular Medicine ,business ,medicine.drug - Abstract
Summary Rabies is a reemerging and fatal infectious disease in Asia mainly caused by exposure to rabid dogs. Prevention of dog rabies would be the most effective way to stop rabies transmission to humans. However, vaccinating stray dogs in urban and rural areas using conventional vaccines is always difficult and is not cost-effective for use in most areas including China. Further to previous studies from our laboratory, we developed a bait containing the recombinant rabies vaccine and performed a non-parenteral trial in dogs. This vaccine was intranasally administrated once to 46 dogs in solution form with 1 × 10 8.5 PFU and orally to 90 dogs in specially designed baits with 3 × 10 8.5 PFU of the recombinant canine adenovirus. Results showed that about 87.5% (119/136) of the immunized dogs developed virus neutralizing antibodies (VNA). The immune response against rabies in dogs was detectable at 2–3 weeks after administration, reaching a peak by 5–6 weeks. Among the seroconverted animals, 90.8% (108/119) elicited a VNA response for over 24 months. The antibody titer during the 2 years was above 0.5 IU/ml while showing a gradual but slow decline from the 6th week after vaccination. In a challenge experiment of 10 dogs with 60,000 mouse LD 50 of CVS-24 2 years after the vaccination, all the dogs survived. This demonstrated that the recombinant vaccine could be orally administrated and the bait was effective for the oral vaccination of dogs.
- Published
- 2007
15. Factors influencing the antibody response of dogs vaccinated against rabies
- Author
-
William E R Ollier, Anthony R. Fooks, Lorraine M. McElhinney, Lorna J. Kennedy, Mark Lunt, A. Barnes, and David Baxter
- Subjects
Male ,Veterinary medicine ,Aging ,Rabies ,medicine.disease_cause ,Antibodies, Viral ,Cohort Studies ,Dogs ,Species Specificity ,Immunity ,HLA Antigens ,medicine ,Animals ,Dog Diseases ,Treatment Failure ,Mononegavirales ,Lyssavirus ,Polymorphism, Genetic ,General Veterinary ,General Immunology and Microbiology ,biology ,Rabies virus ,Vaccination ,Public Health, Environmental and Occupational Health ,Rhabdoviridae ,biology.organism_classification ,medicine.disease ,Breed ,Infectious Diseases ,Rabies Vaccines ,Immunology ,Molecular Medicine ,Regression Analysis ,Female - Abstract
Since 2000, there has been a legal requirement in the UK that dogs and cats should have an effective rabies vaccination with demonstrable sero-conversion if their owners wish to avoid quarantine on re-entry to the UK. In 2002, 10,483 rabies titres were determined on dogs at the VLA. Statistical analyses assessed the efficacy of each vaccine within different dog breeds. Animal size, age, breed, sampling time and vaccine had significant effects on pass rates and median titres. Our data suggests that a general relationship between animal size and level of antibody response exists and smaller sized dogs elicited higher antibody levels than larger breeds of dog. It was not however, only the magnitude of response immediately following vaccination but also the duration of immunity that varied between breeds of dog. Another observation was that young animals, less than 1-year of age, generated a lower antibody response to rabies vaccination than adults. Considerably higher failure rates were also observed for different vaccines tested. Regression analysis revealed that two vaccines performed equally well, and significantly better than the others tested. The variation in antibody response relating to length of interval of sampling following vaccination is not unexpected and presumably relates to the response kinetics for primary vaccination. These data need to be placed in perspective in order to minimise the risk of rabies being re-introduced into a rabies-free country, especially in the consideration of removing the requirement for serological testing for rabies vaccinated dogs that participate in pet travel schemes.
- Published
- 2007
16. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies
- Author
-
Ye Liu, Anthony R. Fooks, Rongliang Hu, Shoufeng Zhang, and Fei Zhang
- Subjects
Male ,Time Factors ,Rabies ,Genetic Vectors ,Administration, Oral ,Biology ,Adenoviruses, Canine ,medicine.disease_cause ,Antibodies, Viral ,Cat Diseases ,Injections, Intramuscular ,Cell Line ,Rabies vaccine ,Neutralization Tests ,medicine ,Animals ,Neutralizing antibody ,Administration, Intranasal ,Duck embryo vaccine ,Vaccines, Synthetic ,CATS ,General Veterinary ,General Immunology and Microbiology ,Rabies virus ,Public Health, Environmental and Occupational Health ,medicine.disease ,Virology ,Survival Analysis ,Vaccination ,Infectious Diseases ,Rabies Vaccines ,Inactivated vaccine ,Immunology ,biology.protein ,Cats ,Molecular Medicine ,Female ,medicine.drug - Abstract
During the past decade, human rabies caused by cats has ranked the second highest in China. Several recombinant rabies vaccines have been developed for dogs. However, seldom have these vaccines been assessed or used in cats. In this trial, we report the experimental immunization of a recombinant canine adenovirus-rabies vaccine, CAV-2-E3Delta-RGP, in cats. Thirty cats were inoculated with the recombinant vaccine intramuscularly, orally and intranasally, respectively. Safety and efficacy studies were undertaken using the fluorescent antibody virus neutralization (FAVN) test and evaluated. Results showed that this recombinant vaccine is safe for cats as demonstrated by the three different routes of administration. The vaccine stimulated an efficient humoral response in the vaccinated cats when 10(8.5)PFU/ml of the recombinant vaccine was injected intramuscularly in a single dose. The neutralizing antibody level increased above 0.5IU/ml at 4 weeks after the vaccination. The mean antibody level ranged from 0.96+/-0.26 to 4.47+/-1.57IU/ml among individuals, and the antibody levels were elicited for at least 12 months. After this period, the immunized cats survived the challenge of CVS-24 and an obvious anemnestic and protective immune response was stimulated after the challenge. The immune response occurred later than the inactivated vaccine and the overall antibody level in the vaccinated cats was lower, but it was sufficient to confer protection of cats against infection. This demonstrated that a single, intramuscular dose of CAV-2-E3Delta-RGP stimulated a long-lasting protective immune response in cats and suggested that CAV-2-E3Delta-RGP could be considered as a potential rabies vaccine candidate for cats.
- Published
- 2007
17. Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe
- Author
-
Ashley C. Banyard, Luis M. Hernández-Triana, Anthony R. Fooks, Nicholas Johnson, Karen L. Mansfield, Daniel L. Horton, and Lorraine M. McElhinney
- Subjects
Rift Valley fever virus ,030231 tropical medicine ,Biology ,Abortion ,Antibodies, Viral ,Zoonotic disease ,Virus ,03 medical and health sciences ,0302 clinical medicine ,Zoonoses ,Immunology and Microbiology(all) ,medicine ,Animals ,Humans ,Rift Valley fever ,Rift valley fever ,030304 developmental biology ,0303 health sciences ,General Veterinary ,General Immunology and Microbiology ,Viral Vaccine ,Public Health, Environmental and Occupational Health ,Viral Vaccines ,medicine.disease ,veterinary(all) ,Virology ,3. Good health ,Europe ,Vaccination ,Culicidae ,Infectious Diseases ,Africa ,Molecular Medicine ,Vaccine ,Encephalitis - Abstract
Rift Valley fever virus (RVFV) is a mosquito-borne virus, and is the causative agent of Rift Valley fever (RVF), a zoonotic disease characterised by an increased incidence of abortion or foetal malformation in ruminants. Infection in humans can also lead to clinical manifestations that in severe cases cause encephalitis or haemorrhagic fever. The virus is endemic throughout much of the African continent. However, the emergence of RVFV in the Middle East, northern Egypt and the Comoros Archipelago has highlighted that the geographical range of RVFV may be increasing, and has led to the concern that an incursion into Europe may occur. At present, there is a limited range of veterinary vaccines available for use in endemic areas, and there is no licensed human vaccine. In this review, the methods available for diagnosis of RVFV infection, the current status of vaccine development and possible implications for RVFV emergence in Europe, are discussed.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.